ReviewCurrent pharmaceutical design2025
Exploring the Multifaceted Metabolic Pathology and Mechanisms of NAFLD: A Bibliometric Analysis and an In-depth Review.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, affecting about a quarter of the world's population. As the prevalence of obesity and metabolic syndrome rises, NAFLD is projected to become the leading cause of cirrhosis in the coming years. NAFLD is a complex disease whose pathophysiology mainly focuses on metabolic dysfunction and intestinal microecological dysregulation. Shifts between free fatty acid (FFA) metabolism and cell damage could be of major interest in finding new therapeutic targets. However, current public understanding of these diseases remains limited. Based on bibliometrics and extensive studies, this study explored the mechanisms by which FFAs regulate the occurrence of NAFLD. This review not only focuses on the role of the vicious cycle derived from FFA metabolic disorders, ecological disorders, and liver damage immunity concerning diabetes mellitus type 2 and NAFLD but also discusses the mechanisms involved in them.
Indexed as
Identifiers
40264325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.